Vifor Pharma Group | December 15, 2021
Global biotechnology leader CSL Limited and Vifor Pharma Ltd, a global specialty pharmaceutical company with leadership in iron deficiency, nephrology & cardio-renal therapies, announced that they have entered into a definitive agreement for CSL to acquire Vifor Pharma for an aggregate equity value for Vifor Pharma of US$ 11.7 / CHF 10.9 billion.
CSL has offered to acquire Vifor Pharma in an all-cash tender offer of US$179.25 per share, payable in U.S. dollars.1 The offer assumes a dividend of CHF 2 expected to be declared at the AGM of 26 April, consistent with past practice.
The tender offer represents an implied premium of approximately 61% to the unaffected closing price of Vifor Pharma on 1 December 2021 and a 47% premium to Vifor Pharma’s unaffected 1-month VWAP as of 1 December 2021.2
Patinex AG, Vifor Pharma’s largest shareholder holding 23.2% has agreed to tender its shares into the offer.
The Transaction remains subject to the conditions and further terms including:
Minimum acceptance rate of 80% of all Vifor Pharma shares on a fully diluted basis; and
further customary offer conditions, including regulatory approvals.
The tender is currently expected to commence around 18 January 2022 and the transaction is expected to complete around mid-2022.
The Board of Directors of Vifor Pharma considers that the proposed transaction respects the interests of all stakeholders and is unanimously recommending the offer to shareholders. There is committed financing for the deal and a strong commitment to pursue regulatory clearances.
“Vifor Pharma's strategy has been to focus towards continuing being a market leader in iron deficiency, nephrology and cardio-renal therapies. The offer provides an excellent strategic opportunity for Vifor Pharma to optimize future market opportunities from a position of strength and to create substantial value for all stakeholders.”
Jacques Theurillat, Chairman of the Board of Directors Vifor Pharma Group
The transaction will enable Vifor Pharma to leverage CSL’s global reach, balance sheet and capabilities to bring more products to patients within its key categories. The transaction also enables Vifor Pharma to accelerate growth in cardiovascular-metabolic, renal and transplant.
Centerview Partners UK LLP is acting as exclusive financial advisor to Vifor Pharma on the transaction.
IFBC have been retained as Fairness Opinion providers by the Vifor Pharma Board of Directors.
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange
CSL is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus- provides life-saving products to more than 100 countries and employs more than 25,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.
KromaTiD Inc | January 14, 2022
KromaTiD is excited to announce early access to our KromaTiD Pinpoint FISH TP53/CEP17 Kit, our new product designed to supply the highest resolution, lowest background, and lowest limit of detection available.
KromaTiD's Pinpoint FISH™ Kit, allows for better hybridization conditions and eliminating strand degradation steps. Pinpoint FISH™ allows researchers to expand beyond the capabilities of conventional FISH probes to detect smaller targets and design ultra-high specificity tests. Our technology is fully compatible with your standard FISH equipment/conditions and BAC probes and works with your established samples, workflow, and imaging system.
"Single-cell genomic measurements from KromaTiD have unique capabilities to analyze and understand the underlying genomic drivers of human disease. Pinpoint FISH has an unmatched resolution, extraordinary ease of use, consistency from analysis to analysis, and an unprecedented ability to distinguish fine genomic structural variation" Dr. Tompkins continues, "While this is the first catalog product from KromaTiD, we have a ten-year history of building a custom assay for Pharma and Biotech companies based on the PPF and dGH platforms. As we begin to build out a comprehensive line of blood cancer measurement kits, we are delighted to bring Pinpoint FISH to a worldwide market". Pinpoint FISH™ is available now from KromaTiD for researchers' use in oligonucleotide-based FISH assays.
Christopher Tompkins, KromaTiD's Chief Technology Officer
About KromaTiD, Inc.
KromaTiD is transforming the fields of genome engineering through the discovery and characterization of genomic structural changes that help leading gene editing and pharmaceutical companies advance therapies to market. KromaTiD offers a powerful suite of products and services for studying genomic rearrangements, custom assay development services and preclinical research support. KromaTiD's proprietary Pinpoint FISH™ and directional Genomic Hybridization platforms (dGHTM) have applications throughout genomics, supplying direct, definitive data on structural variations that no other technologies can provide. We provide the essential genomic structural context to sequence.
Twelve Consulting Group, | February 11, 2022
Twelve Consulting Group, a consultancy firm specializingin designing and delivering cloud-based solutions, has formalized its partnership with Celonis, the global leader in execution management.
This partnership combines Twelve CG’s technology consulting expertise with Celonis’ market leading process mining and execution management capabilities, enabling customers to optimize their business operations, identify inefficiencies and unlock their full execution capacity.
The Celonis Execution Management System (EMS) provides companies with a modern way to understand and execute their business processes, eliminating billions of dollars in inefficiencies. The EMS powers all facets of business execution, including real-time data ingestion, process and task mining, planning and simulation, visualization and daily management, and targeted action flows to course correct in real-time.
“By partnering with Celonis, we’ll be able to help our customers identify broken processes and execution gaps. And in addition, we can use the Celonis platform to fix those process issues and unlock efficiencies and value. This collaboration brings together the strengths of both organizations to deliver exceptional business outcomes and improve performance for our joint customers.”
Jon Howard, Director of Solution Innovation at Twelve CG
“Today’s businesses need to be able to see and understand processes before they can effectively act. Our Execution Management System helps customers identify and fix failing business processes, and addresses every facet of execution management from analytics, to strategy and planning, management, actions and automation,” said Nicole Gallant, VP Partner Management North America at Celonis. “Partnering with Twelve CG will help enterprises close the execution gaps that have been holding them back from achieving full execution capacity.”
About Twelve Consulting Group
Founded in 2013 by Jill King, Twelve Consulting Group leverages leading cloud-based technologies to help customers unlock potential with smarter data. Twelve CG works with 100+ customers across the CPG, Pharmaceutical and Technology industries to solve mission critical business challenges with speed, accuracy and agility.
MedX Health Corp | January 28, 2022
Teledermatology company MedX Health Corp. is pleased to announce the launch of MedX Screening Services to be offered at two locations in Ottawa, Canada – ProMed Pharmacy, an independent, pharmacist owned pharmacy enterprise, and Dura Wellness Clinic a retail, clinical focused esthetic services group. Both locations will now offer MedX scanning services and accept walk-in patients.
"This represents the next step in our business plan for North America. ProMed Pharmacy, under the Leadership of Lubna Fawaz, is a perfect model of modern health care delivery as it integrates many services and, most importantly, telehealth services on demand for their patients. Patients can now enter the pharmacy and have a telemedicine consult with a General Practitioner and receive an immediate referral to the Dermsecure Screening Service on site. Incorporating a telemedicine consult with a General Practitioner is a vital step to make DermSecure screening services easily accessible to the public by facilitating both the referral and the screening at the same location."
MedX VP of North American Sales, Paul Ziemer
The addition of ProMed Pharmacy to MedX's Pharmacy network will allow for the "Walk-in-Patient" to get service for their Dermatology concerns if they do not have a Family Doctor or do not have time to get a direct referral.
"MedX remains focused on expanding its footprint into existing and new target markets, and our team is continuing to establish and accelerate many new commercial relationships and partnerships," stated Mike Druhan, MedX President, Dermatology Services. "I remain confident in our team’s ability to expand MedX's teledermatology platform to new markets and greatly improve outcomes for those dermatology patients seeking high-quality, virtual services."
Teledermatology is a subspecialty of dermatology that offers safe and effective virtual care – patient screening and assessment – eliminating the need for in-person appointments with a dermatologist. MedX is a global leader in teledermatology through its high-definition image capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process. MedX's SIAscopy® is the only technology globally that captures five high-resolution images of suspicious moles, lesions and skin conditions, including four spectrophotometric images 2mm below the skin's surface. This technology provides detailed patient scans for virtual dermatological assessment by a certified dermatologist within 72 hours.
About MedX Health Corp
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey.